Diagnosis, pathogenesis and treatment of myositis: recent advances.
Carstens PO, Schmidt J.
Clin Exp Immunol. 2014 Mar;175(3):349-58. doi: 10.1111/cei.12194.
Clinical pearls and promising therapies in myositis.
Connolly CM, Paik JJ.
Expert Rev Clin Immunol. 2023 Jul-Dec;19(7):797-811. doi: 10.1080/1744666X.2023.2212162. Epub 2023 May 18.
Idiopathic inflammatory myopathies: a review.
Ashton C, Paramalingam S, Stevenson B, Brusch A, Needham M.
Intern Med J. 2021 Jun;51(6):845-852. doi: 10.1111/imj.15358.
Immune Checkpoint Inhibitor-induced Myositis.
Jayan A, Mammen AL, Suarez-Almazor ME.
Rheum Dis Clin North Am. 2024 May;50(2):281-290. doi: 10.1016/j.rdc.2024.02.003. Epub 2024 Mar 12.
Current Classification and Management of Inflammatory Myopathies.
Schmidt J.
J Neuromuscul Dis. 2018;5(2):109-129. doi: 10.3233/JND-180308.
Atypical proliferative myositis: original MR description with pathologic correlation: case report.
Jarraya M, Parva P, Stone M, Klein MJ, Guermazi A.
Skeletal Radiol. 2014 Aug;43(8):1155-9. doi: 10.1007/s00256-014-1849-y. Epub 2014 Mar 8.
Recurrent FOS rearrangement in proliferative fasciitis/proliferative myositis.
Makise N, Mori T, Motoi T, Shibahara J, Ushiku T, Yoshida A.
Mod Pathol. 2021 May;34(5):942-950. doi: 10.1038/s41379-020-00725-2. Epub 2020 Dec 14.
Autoimmune inflammatory myopathies.
Dalakas MC.
Handb Clin Neurol. 2023;195:425-460. doi: 10.1016/B978-0-323-98818-6.00023-6.
Scleromyositis: A distinct novel entity within the systemic sclerosis and autoimmune myositis spectrum. Implications for care and pathogenesis.
Giannini M, Ellezam B, Leclair V, Lefebvre F, Troyanov Y, Hudson M, Senécal JL, Geny B, Landon-Cardinal O, Meyer A.
Front Immunol. 2023 Jan 26;13:974078. doi: 10.3389/fimmu.2022.974078. eCollection 2022.
[Myositis].
Grau JM, Casademont J.
Med Clin (Barc). 1992 Jul 4;99(6):218-20.
